Posted by Michael Wonder on 09 Mar 2020
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthma
9 March 2020 - NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.
It’s common for NICE to reject drugs at this first draft stage, asking the manufacturer to either drop its price or provide further data or analyses to help with the number crunching.
In the first draft guidance NICE acknowledged that Dupixent is effective for preventing exacerbations in people with severe asthma with type 2 inflammation, compared with standard care.
